Imaging androgen receptors in breast cancer with 18F-fluoro-5α-dihydrotestosterone PET: a pilot study

H Jacene, M Liu, SC Cheng, A Abbott… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Most breast cancers express androgen receptors (ARs). This prospective imaging substudy
explored imaging of ARs with 18F-fluoro-5α-dihydrotestosterone (18F-FDHT) PET in …

Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies

CM Venema, LH Mammatas, CP Schröder… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor
receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer …

[HTML][HTML] [18F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review

L Filippi, L Urso, O Schillaci, L Evangelista - Diagnostics, 2023 - mdpi.com
The aim of this systematic review is to provide a comprehensive overview of the role of fluoro-
5α-dihydrotestosterone ([18F]-FDHT) for the in vivo imaging of androgen receptors (AR) …

[HTML][HTML] Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer

J Boers, CM Venema, EFJ de Vries… - European Journal of …, 2021 - Elsevier
Background The androgen receptor (AR) is a potential target in metastatic breast cancer
(MBC), and 16β-[18 F]-fluoro-5α-dihydrotestosterone positron emission tomography ([18 F] …

18F-Fluoroestradiol (FES) and18F-Fluorodeoxyglucose (FDG) PET imaging in male breast cancer

L Peterson, P Manohar, V Wu, I Jenkins, A Novakova… - 2018 - Soc Nuclear Med
54 Objectives: Breast cancer is an uncommon disease in men. Because of the rarity of the
disease, PET imaging results and guidelines for optimal management of male breast cancer …

[HTML][HTML] Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?

L Evangelista, D Rubello, G Saladini - European journal of nuclear …, 2012 - Springer
As breast cancer becomes metastatic, it becomes incurable and the goals of treatment are
palliation of symptoms, prolongation of survival, and maintenance or improvement of the …

Antiandrogen Therapy Radiosensitizes Androgen Receptor–Positive Cancers to 18F-FDG

I Singaravelu, H Spitz, M Mahoney… - Journal of Nuclear …, 2022 - Soc Nuclear Med
A subset (35%) of triple-negative breast cancers (TNBCs) expresses androgen receptor
(AR) activity. However, clinical trials with antiandrogen drugs have shown limited efficacy …

[HTML][HTML] PET imaging agents (FES, FFNP, and FDHT) for estrogen, androgen, and progesterone receptors to improve management of breast and prostate cancers by …

JA Katzenellenbogen - Cancers, 2020 - mdpi.com
Many breast and prostate cancers are driven by the action of steroid hormones on their
cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit …

[HTML][HTML] Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics

T Jia, Q Lv, B Zhang, C Yu, S Sang, S Deng - BMC Medical Imaging, 2023 - Springer
Objective In the present study, we mainly aimed to predict the expression of androgen
receptor (AR) in breast cancer (BC) patients by combing radiomic features and …

18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor–Positive Bone-Dominant Metastatic Breast Cancer

I Makhlin, KE Korhonen, ML Martin, J Gillman… - Radiology: Imaging …, 2022 - pubs.rsna.org
Fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT has shown promise for use in
assessing treatment response in patients with bone-only or bone-dominant (BD) metastatic …